Shukra Pharmaceuticals Limited has completed the allotment of 46,43,000 convertible equity warrants to promoter entities on a preferential basis, as announced following the Board of Directors meeting held on January 28, 2026. The allotment was conducted at an issue price of ₹34 per warrant, with the company receiving an upfront payment of ₹3,94,65,500 representing 25% of the total consideration.

Warrant Allotment Details

The Board approved the allotment to five promoter entities under the SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018. The allotment follows the special resolution passed by shareholders at the extraordinary general meeting held on November 01, 2025, and the in-principle approval granted by BSE Limited on January 9, 2026.

Conversion Terms and Timeline

Each warrant is convertible into one fully paid-up equity share with a face value of ₹1 each. The warrant holders must pay the balance consideration of ₹34 per warrant, aggregating to ₹11,83,96,500, representing 75% of the total consideration upon exercise of the conversion option. The warrants carry an 18-month conversion period from the allotment date, allowing holders to exercise conversion in one or more tranches.

The total potential fundraising from this preferential issue amounts to ₹15,78,62,000 upon full conversion of all warrants. Currently, the allotment does not change the company's paid-up share capital, as the warrants represent conversion rights rather than immediate equity shares.

Impact on Shareholding Pattern

The conversion of warrants will result in changes to the promoter shareholding pattern. Post-conversion, the collective promoter holding will increase from 21,77,35,600 shares (49.73%) to 22,23,78,600 shares (50.26%). Anar Project Private Limited will maintain the largest individual holding at 18.86% post-conversion, followed by Parshva Texchem India Private Limited at 17.27%.

Regulatory Compliance

The warrant allotment complies with SEBI ICDR Regulations and follows the preferential allotment framework under the Companies Act, 2013. The Board meeting commenced at 7.10 p.m. and concluded at 7.50 p.m. on January 28, 2026. Any unexercised warrants beyond the 18-month period will lapse, and the amounts paid by warrant holders will be forfeited by the company.

Shukra Pharmaceuticals Limited has successfully concluded its postal ballot process through remote e-voting, with shareholders providing overwhelming support for continuing the directorship of an independent director beyond the statutory age limit. The company announced the voting results on January 05, 2026, following the completion of the e-voting period.

Postal Ballot Resolution Details

The postal ballot focused on a single special resolution to approve the continuation of Mr. Jitendra Somchand Shah (DIN: 01609325) as Non-Executive Independent Director beyond the age of 75 years in his current tenure. The resolution was deemed necessary as per regulatory requirements for directors exceeding the standard age limit.

Voting Process and Timeline

The remote e-voting process was conducted exclusively through electronic means, in accordance with MCA circulars and SEBI regulations. The voting commenced on Thursday, December 04, 2025, at 09:00 AM (IST) and concluded on Saturday, January 03, 2026, at 05:00 PM (IST). National Securities Depository Limited (NSDL) provided the e-voting platform for the process.

Overwhelming Shareholder Support

The voting results demonstrated strong shareholder confidence in the director's continuation. Out of 23,733 total shareholders on the record date, 50 members participated in the voting process. The resolution received exceptional support with 99.99% votes in favor.

Category-wise Voting Breakdown

The voting pattern showed strong support across different shareholder categories. Promoter and Promoter Group held 223,135,600 shares and cast 9,760,000 votes entirely in favor of the resolution. Public Non-Institutions category, holding 214,743,840 shares, cast 49,884 votes with 48,776 in favor and 1,108 against.

Regulatory Compliance and Scrutiny

Mrs. Rupal Patel, Practicing Company Secretary (C.P. No. 3803), served as the appointed scrutinizer for the postal ballot process. The scrutinizer's report confirmed the validity of the voting process and declared the resolution as passed with the requisite majority. The entire process was conducted in compliance with Section 108 and Section 110 of the Companies Act, 2013, and SEBI Listing Regulations.

The company has fulfilled all regulatory requirements by submitting the voting results to BSE Limited and uploading the details on its website for stakeholder transparency.